GeneH Excellence Hub for Advancing Innovation in Gene Therapy
- Coordinator
- Universidade De Coimbra, Portugal
- Runs
- 1 January 2025 to 31 December 2028
- Status
- Running
- EU funding
- €4.9m
- Total cost
- €4.9m
- Partners
- 13 organisations in 2 countries
- Type
- Coordination and Support Action
- Grant agreement
- 101186939
What the project is doing
In the project's own words, from its summary on CORDIS.
GeneH proposes to create an excellence hub in gene therapy through strategic partnerships within and beyond Widening countries. Despite gene therapy's recognized priority in genomic medicine and its potential for high-curative economic impact, challenges persist in its development process, from conceptualization to commercialization. GeneH intends to address these challenges by serving as a catalyst for overcoming barriers and expediting research translation.
To achieve this, GeneH will establish a robust and sustainable hub that builds upon already established ecosystems in the field and recent H2020 WIDENING projects to implement centers of excellence in gene therapy (GeneT in PT and CTGCT in SL). The academic partners at its core, namely, the University of Coimbra (UC) in Portugal and the National Institute of Chemistry (KI/NIC) in Slovenia , have reached substantial achievements by partnering with industry (Bluepharma, Biocant Park, Biosistemika, Jafral), hospitals (CHUC EPE), policy makers (CCDRC, RRA LUR), ecosystem/innovation supporters (SIH EEIG, IPN), and patient associations (APAHE, ZOPS).
Partners in the two ecosystems share a common goal: treating life-threatening or chronically debilitating diseases considered incurable. By harnessing the combined expertise and resources of its partners, GeneH aims to drive cross-sectoral collaboration through its 4-helix network, in a multidimensional approach that will gather further investment, address ethical and regulatory aspects, implement de-risking approaches, educational and training programes, joint R&I programs, and prepare the path for clinical trials of new gene therapy products, while actively engaging society.
By positioning itself as a leading hub in gene therapy, in line with regional, national, and European strategies, GeneH seeks to contribute to European competitive leadership globally, advancing healthcare, fostering economic growth, and making a positive societal impact.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidade De Coimbra | Coimbra | Portugal | Coordinator |
| Associacao Portuguesa De Ataxias Hereditarias | Castro Marim | Portugal | Participant |
| Biocant Associacao De Transferencia De Tecnologia | Cantanhede | Portugal | Participant |
| Bluepharma - Industria Farmaceuticasa | Coimbra | Portugal | Participant |
| Comissao De Coordenacao E Desenvolvimento Regional Do Centro | Coimbra | Portugal | Participant |
| Instituto Pedro Nunes Associacao Para a Inovacao E Desenvolvimento Em Ciencia E Tecnologia | Coimbra | Portugal | Participant |
| Unidade Local De Saude De Coimbra Epe | Coimbra | Portugal | Participant |
| Biosistemika, Raziskave in Razvoj Doo | Ljubljana | Slovenia | Participant |
| Jafral, Biotehnoloske Raziskave Inrazvoj, Doo | Ljubljana | Slovenia | Participant |
| Kemijski Institut | Ljubljana | Slovenia | Participant |
| Regionalna Razvojna Agencija - Ljubljanske Urbane Regije Zavod | Ljubljana | Slovenia | Participant |
| Slovensko Inovacijsko Sticisceevropsko Gospodarsko Interesnozdruzenje | Ljubljana | Slovenia | Participant |
| Zveza Organizacij Pacientov Ter Uporabnikov Zdravstvenih in Socialno Varstvenih Storitev Slovenije | Ljubljana | Slovenia | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI